Pre-IPO Eastenova (Chengdu) Biotechnology- The Commercialization of XH301 May Be Lower than Expected
​Eastenova face challenges with non-core assets/lagging product development, impacting overall profitability/market potential. Inefficient assets...
369 Views
Eastenova (东方妍美) Pre-IPO: Recalibration of Potentials
​China's regenerative medicine specialist Eastenova aims to raise $100 million through a Hong Kong listing. Our research indicates a need to...
228 Views
ECM Weekly (4 August 2025)-Meituan, LG CNS, Wuxi AppTec, SICC, NSDL, Aditya Info, GigaDevice, WeWork
Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.
773 Views
No more insights